^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IL13RA2 overexpression

i
Other names: IL13RA2, Interleukin 13 Receptor Subunit Alpha 2, Interleukin-13 Receptor Subunit Alpha-2, Interleukin 13 Receptor Alpha 2, IL-13 Receptor Subunit Alpha-2, Cancer/Testis Antigen 19, IL-13R Subunit Alpha-2, IL-13R-Alpha-2, IL-13RA2, IL-13R, IL13BP, CT19, Interleukin 13 Receptor Alpha 2 Chain, Interleukin 13 Binding Protein, Interleukin-13-Binding Protein, CD213a2 Antigen, CD213A2, IL13RA2, CD213a2, IL13R
Entrez ID:
Related biomarkers:
over1year
Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide. (PubMed, Cancers (Basel))
Therefore, the Pep-1-Phor21-mediated targeting of IL-13Rα2 is a potentially novel therapeutic strategy for TNBC. Given that tumor cells can be selectively sensitized to Pep-1-Phor21 via the epigenetic up-regulation of IL-13Rα2, a combined adjuvant approach involving Pep-1-Phor21 and epigenetic inhibitors may be an effective strategy.
Journal
|
IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
|
IL13RA2 expression • IL13RA2 overexpression
3years
Combinatorial immune checkpoint inhibitors for targeted intratumoral delivery in GBM (SNO 2021)
We next designed a heterodimeric construct which can combinatorially target CTLA4 and PD1 while also directing the ICI therapy to GBM. These constructs in conjunction with other immune stimulants like cytotoxic therapies are intended to facilitate the interaction between T cells and GBM tumor cells directly in a tumor microenvironment.
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
|
IL13RA2 overexpression